---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000026"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:16:25.250762+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10

## Summary
- Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).
- GAAP net income $24.3M ($0.47 diluted EPS) vs $5.0M ($0.10) a year ago.
- Adjusted non-GAAP net income $24.6M ($0.47 EPS) vs $13.6M ($0.27) in Q1 2021.
- CEO cites strong sales of recent complex product launches; optimistic for continued growth.

## SEC filing metadata
- accession: 0001297184-22-000026
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000026/0001297184-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000026/amph-20220509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000026
- JSON: https://secwatch.observer/filing/0001297184-22-000026.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.